LAEKNA-B (02105) rose nearly 7% during the morning session. At the time of writing, the stock was up 5.88%, trading at HK$14.23 with a turnover of HK$9.34 million. On January 14, LAIKE Medicine announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118. LAE118 is a novel, pan-mutant selective PI3Kα inhibitor independently developed by Laike for the treatment of patients with solid tumors harboring PIK3CA mutations. PI3Kα mutations are relatively common in patients with breast cancer, colorectal cancer, lung cancer, endometrial cancer, and other cancers. Currently approved PI3Kα inhibitors globally lack selectivity for mutant types; they exhibit poor tolerability due to strong activity against the wild-type and are prone to developing resistance.